Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 5000 participants.
Also called NCT02762851
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 5,000 participants
- Sponsor
- Registry
-
NCT02762851
-
- Other papers using this trial's data
- Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Cameroon, China, India, Kenya, Lebanon, Mozambique, Nigeria, Philippines, Saudi Arabia, Sudan, Uganda, United Arab Emirates, Zambia
- Registry status
- Unknown status
Technical summary
Registry record NCT02762851. Randomized; quadruple masking; primary purpose treatment. Start 2016-06 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)
- Acronym
- RCT-IVVE
- Condition
- Heart Failure
- Condition
- Influenza
- Intervention (Other)
- Sterile saline
- Intervention (Drug)
- inactivated trivalent influenza vaccine
- Lead sponsor
- McMaster University
Record details
- Record id
cardio:ct-nct02762851- Content hash
5afcd30ab39d35d5fad78d8ce8db3e052ff82fdaf16bc75cf0ff1b096c39ecfb